Literature DB >> 10772956

Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts.

M Grano1, G Mori, V Minielli, F P Cantatore, S Colucci, A Z Zallone.   

Abstract

Breast cancers commonly cause osteolytic metastases in bone, a process that is dependent upon osteoclast-mediated bone resorption, but the mechanism responsible for tumor-mediated osteoclast activation has not yet been clarified. In the present study we utilized a well-known human breast cancer cell line (MDA-231) in order to assess its capability to influence osteoclastogenesis in human bone marrow cultures and bone resorption in fully differentiated osteoclasts. We demonstrated that conditioned medium (CM) harvested from MDA-231 increased the formation of multinucleated TRAP-positive cells in bone marrow cultures. Bone resorption activity of fully differentiated human osteoclasts and of osteoclast-like cell lines, from giant cell tumors of bone (GCT), was highly increased by the presence of MDA-231 CM. Moreover, while MDA-231 by themselves did not produce IL-6 tumor cell, CM increased the secretion of IL-6 by primary human osteoclasts and GCT cell lines compared to untreated controls. These data suggest that MDA-231 produce osteoclastic activating factor(s) that increase both osteoclast formation in bone marrow culture and bone resorption activity by mature cells. Moreover, breast cancer cells stimulate IL-6 secretion by osteoclasts that is one of the factors known to supports osteoclastogenesis. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772956     DOI: 10.1006/bbrc.2000.2569

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  High level interleukin-6 in the medium of human pancreatic cancer cell culture suppresses production of neurotransmitters by PC12 cell line.

Authors:  Rong Li; Jian Hou; Qing Xu; Qing-Jun Liu; Yi-Jun Shen; Gary Rodin; Madeline Li
Journal:  Metab Brain Dis       Date:  2011-11-23       Impact factor: 3.584

2.  Tungsten Promotes Sex-Specific Adipogenesis in the Bone by Altering Differentiation of Bone Marrow-Resident Mesenchymal Stromal Cells.

Authors:  Alicia M Bolt; Michael P Grant; Ting Hua Wu; Manuel Flores Molina; Dany Plourde; Alexander D R Kelly; Luis Fernando Negro Silva; Maryse Lemaire; Jennifer J Schlezinger; Fackson Mwale; Koren K Mann
Journal:  Toxicol Sci       Date:  2016-02-09       Impact factor: 4.849

3.  Tungsten targets the tumor microenvironment to enhance breast cancer metastasis.

Authors:  Alicia M Bolt; Valérie Sabourin; Manuel Flores Molina; Alice M Police; Luis Fernando Negro Silva; Dany Plourde; Maryse Lemaire; Josie Ursini-Siegel; Koren K Mann
Journal:  Toxicol Sci       Date:  2014-10-15       Impact factor: 4.849

Review 4.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09

Review 5.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

6.  Cellular mechanisms of bone resorption in breast carcinoma.

Authors:  N C Hunt; Y Fujikawa; A Sabokbar; I Itonaga; A Harris; N A Athanasou
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

7.  Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.

Authors:  Audrey Lamora; Mathilde Mullard; Jérôme Amiaud; Régis Brion; Dominique Heymann; Françoise Redini; Franck Verrecchia
Journal:  Oncotarget       Date:  2015-06-10

8.  Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.

Authors:  Valeria Simone; Sabino Ciavarella; Oronzo Brunetti; Annalisa Savonarola; Mauro Cives; Marco Tucci; Giuseppina Opinto; Eugenio Maiorano; Franco Silvestris
Journal:  BMC Cancer       Date:  2015-10-14       Impact factor: 4.430

9.  Use of ibandronate in the prevention of skeletal events in metastatic breast cancer.

Authors:  Bianca Devitt; Sue-Anne McLachlan
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

10.  Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.

Authors:  T Bachelot; I Ray-Coquard; C Menetrier-Caux; M Rastkha; A Duc; J-Y Blay
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.